Trial · NCT07256236
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
NCT07256236, Phase 2, Recruiting, Fujian Cancer Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer. Trials, record NCT07256236. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07256236
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
- NCT number
- NCT07256236
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 89 participants, estimated
- Lead sponsor
- Fujian Cancer Hospital
- Conditions
- Cervical Cancer
- Interventions
- Sacituzumab tirumotecan, QL1706
- First posted
- 2025-12-01
- Last updated
- 2026-03-30
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | Up to approximately 24 months | ORR is defined as the percentage of patients who achieve complete response(CR) or partial response (PR), as assessed investigator per RECIST 1.1 |
| Secondary | Overall Survival(OS) | From treatment administration up to a maximum duration of 24 months. | Time from start of treatment to death due to any cause. |
| Secondary | Progression Free Survival(PFS) | From treatment administration up to a maximum duration of 24 months. | The time from the beginning of the patient's treatment to the disease progression per RECIST 1.1 based on investigator or death due to any cause, whichever occurs first. |
| Secondary | Duration of Response(DoR) | Through study completion, an expected average of 24 months. | DoR is defined as the time from the date of first documented CR or PR until date of documented disease progression per RECIST 1.1, as assessed by investigator or death due to any cause, whichever occurs first. |
| Secondary | Disease Control Rate (DCR) | From treatment administration up to a maximum duration of 24 months. | DCR is defined as the percentage of patients who achieve CR, PR or stable disease (SD), as assessed by investigator per RECIST 1.1 |
| Secondary | Percentage of Participants With Adverse Events (AEs) | Up to approximately 24 months. | Number of participants with adverse events (AEs) according to CTCAE 5.0 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07256236
GET https://conductscience.org/api/trials/v1/NCT07256236/registered